Biosimilars: Bridging the Gap in Biologics, Access, and Affordability
Journal of Pharmaceutical and BioTech Industry · 2026
DOI: 10.3390/jpbi3010002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and BioTech Industry, 2026. Verfasst von Afza Rizwan und 3 weiteren Autor:innen. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
There is a growing global demand for cost-effective alternatives to high-priced biologic therapies, which has significantly accelerated the development of biosimilars and positioned them as sustainable and affordable treatment options. Biosimilars include therapeutic products such as monoclonal antibodies, soluble receptors, growth factors, and hormones that demonstrate comparable efficacy, safety, and quality to their reference biologics. By providing lower-cost alternatives, biosimilars play a vital role in bridging the affordability gap and expanding patient access to essential, life-saving treatments, particularly in low- and middle-income countries. This review focuses on current Good Manufacturing Practices (cGMPs) in biosimilar development, highlighting critical processes such as cell line engineering, glycosylation optimization, and bioprocess refinement aimed at improving cell culture productivity and product yield while ensuring consistent safety, efficacy, and quality across production batches. Advances in biotechnology, especially in proteomics and advanced analytical characterization, have improved understanding of cellular mechanisms influencing product quality and strengthened comparability with reference biologics. These scientific innovations have enhanced regulatory and clinical confidence, supporting wider acceptance and use amongst patients. In addition, this review examines the evolving global regulatory landscape governing biosimilars and its role in reducing development timelines and costs. Together, scientific innovation, standardized manufacturing practices, and harmonized regulatory frameworks foster competition, accelerate market entry, and ultimately help bridge the gap between innovation and affordability, ensuring equitable and sustainable global access to advanced biologic therapies.
Zitieren
APA
Rizwan, A., Dubey, K., Malhotra, V., & Bhatnagar, S. (2026). Biosimilars: Bridging the Gap in Biologics, Access, and Affordability. Journal of Pharmaceutical and BioTech Industry. https://doi.org/10.3390/jpbi3010002
Vancouver
Rizwan A, Dubey K, Malhotra V, Bhatnagar S. Biosimilars: Bridging the Gap in Biologics, Access, and Affordability. Journal of Pharmaceutical and BioTech Industry. 2026. doi:10.3390/jpbi3010002
BibTeX
@article{Rizwan2026,
author = {Rizwan, Afza and Dubey, Karan and Malhotra, Vishal and Bhatnagar, Seema},
title = {Biosimilars: Bridging the Gap in Biologics, Access, and Affordability},
journal = {Journal of Pharmaceutical and BioTech Industry},
year = {2026},
doi = {10.3390/jpbi3010002}
}
EUVIMED